Adhesive containing microparticles

Information

  • Patent Grant
  • 11058793
  • Patent Number
    11,058,793
  • Date Filed
    Friday, May 11, 2012
    11 years ago
  • Date Issued
    Tuesday, July 13, 2021
    2 years ago
Abstract
Methods for forming and incorporating microparticles containing one or more active agents into adhesives are described. The methods involve spray drying a liquid of the one or more active agents and obtaining the active agent in a particulate form. The dry powder is then blended or otherwise incorporated with the adhesive of interest. Also described are various medical products utilizing the adhesive and one or more active agents in microparticle form, and related methods of use.
Description
FIELD

The present invention relates to adhesives containing microparticles of one or more active agents, methods for incorporating microparticles of actives into an adhesive, and products using such adhesives.


BACKGROUND

A wide array of medical products use adhesive for affixing the product onto a user's skin. As will be appreciated, it is desirable to include one or more active agents such as antimicrobial agents in the medical product or adhesive to prevent or at least minimize microbial growth or reproduction along the skin, as such can readily lead to infection and other undesirable conditions.


Accordingly, artisans have attempted to incorporate a wide range of antimicrobial agents into medical products or materials. Although certain agents have been incorporated into adhesives, effective incorporation into an adhesive composition presents a formidable technical challenge. It is difficult to efficiently disperse such agents within the adhesive. Furthermore, certain antimicrobial agents undergo a loss in efficacy upon incorporation in an adhesive formulation due to the presence of solvents or other components in the adhesive.


Accordingly, it would be desirable to provide a method for incorporating one or more active agents and particularly an antimicrobial agent into an adhesive formulation such that the agent is effectively dispersed and retains its efficacy when residing in the adhesive.


SUMMARY

The difficulties and drawbacks associated with previously known compositions, products, and practices are addressed in the present methods, adhesive compositions, products using such compositions and related methods of use.


In one aspect, the present subject matter provides an adhesive composition comprising an adhesive and microparticles dispersed in the adhesive. The microparticles include a matrix material and at least one active agent.


As will be realized, the subject matter is capable of other and different embodiments and its several details are capable of modifications in various respects, all without departing from the invention. Accordingly, the description is to be regarded as illustrative and not restrictive.







DETAILED DESCRIPTION OF THE EMBODIMENTS

The present subject matter generally provides an adhesive composition comprising microparticles that include one or more active agents. The present subject matter also provides various methods relating to the preparation of the adhesives and microparticles, and various products using such adhesives.


Active Agents and Forming Microparticles


A wide array of one or more active agents can be incorporated in the adhesives described herein. Preferably, the active agents are hydrophilic. Non-limiting examples of preferred active agents include benzocaine, procaine hydrochloride, tetracaine, tetracaine hydrochloride, dibucaine, lidocaine, lidocaine hydrochloride, bupivicaine, dyclonin, etidocaine, mepivicaine, butamen picrate, dimethisoquin hydrochloride, cyclomethylcaine sulfate, and the like; analgesics and anti-inflammatory agents such as buprenorphin, butophanol tartrate, acetaminophen, fentanyl, mefenamic acid, flutenamic acid, diclofenac, oxyphenbutazone, phenybutazone, ibuprofen, flurbiprofen, naproxen, menthol, methyl salicylate, phenol, salicylic acid, benzyl alcohol, camphor, camphorated metacresol, juniper tar, resorcinol, allyl isothiocyanate, capsaicin, and the like; corticosteroids such as alclometasone dipropionate, amcinocide, hydrocortisone, betamethasone dipropionate, betamethasone valerate, desoximetasone, clobetasol propionate, flurandrenolide, halcinonide, halobetasol, estradiol, testosterone, progesterone, fluticasone, clobetasol, dexamethasone, dexonide, fluocinolone acetonide, flucinonide, medroxyprogesterone, mometasone furoate, triamcinolone, and the like; antibiotics such as bacitracin, bacitracin zinc, chlortetracycline hydrochloride, chlorhexadine gluconate, clindamycin, cliquinol, neomycin sulfate, polymyxin B sulfate, erythromycin, gentamicin, sulfathiazole, sulfacetamide, sulfabenzamide, oxytetracycline hydrochloride, tetracycline, and the like; antimicrobial agents such as benzalkonium chloride, chlorhexidine gluconate, hexachlorophene, mafenide acetate, nitrofurazone, nystatin, acetosulfamine, clortrimazole, povidone-iodine, and the like; antifungal agents such as amphotericin B, butoconazole, cetylpyridinium chloride, chlorxylenol, cyclopirox olamine, clioquinol, clotrimazole, sulconazole nitrate, nystatin, oxyconazole, econazole nitrate, ketoconazole, miconazole nitrate, naftifine hydrochloride, pentamycin, pyrrolinitrin, terbinafine, triacetin, and the like; debriding agents such as deoxyribonuclease, collagenolytic, debridement, fibrinolytic or proteolytic enzymes, papain, papain-urea, and the like; antihistamines such as chlorcyclizine hydrochloride, diphenylhydramine hydrochloride, tripelennamine hydrochloride, and the like; antiepileptics such as nitrazepam, meprobamate, clonazepam, and the like; coronary vasodilators such as nitroglycerine, dipyridamole, erythritol, tetranitrate, pentaerythritol tetranitrate, propatyinitrate, and the like; dermatological agents such as retinal, retinol, retinoic acid and their derivatives, hydroxyacids, alphaketoacids, and the like; and other drugs such as benzoyl peroxide, podofilox, masoprocol, nicotine, scopolamine, nitroglycerine, fluorouracil, hydrocolloids, hydroquinone, monobenzone, tretinoin and acyclovir. Preferred drugs for use herein include acne-benzoyl peroxide, Vitamin C, and Vitamin E.


Although the one or more active agent(s) incorporated in the microparticles are preferably hydrophilic, the subject matter includes the incorporation of one or more active(s) that are hydrophobic, and the incorporation of a combination of hydrophilic agents and hydrophobic agents.


The microparticles may also comprise one or more matrix binder, or excipient materials. Preferably, the matrix materials are inert or substantially so. Non-limiting examples of matrix materials include binders such as saccharide binders, protein binders, and synthetic polymer binders; fillers such as plant cellulose, dibasic calcium phosphate, vegetable fats and oils, sugar fillers, calcium carbonate, and magnesium stearate; preservatives such as antioxidants, amino acid preservatives, citric acid, sodium citrate, synthetic preservatives such methyl paraben and propyl paraben; sorbents; and other additives.


Utilizing one or more matrix materials in conjunction with one or more active agent(s) enables a formulator to selectively provide a desired concentration of active in the adhesive composition. Furthermore, in certain applications it may be desired to utilize a relatively high concentration or loading of microparticles in the adhesive. Utilizing a matrix material in the microparticles enables selected or relatively low concentrations of active(s) to be attained.


A preferred method of forming microparticles of one or more actives is spray drying. Spray drying is a method of producing a dry powder from a liquid or slurry by rapidly drying with a hot gas. This is the preferred method of drying of many thermally sensitive materials such as foods and pharmaceuticals. A consistent particle size distribution is a reason for spray drying some industrial products such as catalysts. Air is typically the heated drying media. However, if the liquid is a flammable solvent or the product is oxygen-sensitive then nitrogen can be used.


In forming the preferred embodiment microparticles, one or more active agents are placed in a liquid form, if not already in such form. If any matrix materials are used, those are combined with the active(s). Additional amounts of solvent or liquid medium may be added to adjust viscosity as desired. Dispersants and/or surfactants can be added to promote mixing and/or dispersion of the active agent(s) in the solvent or carrier. The liquid is then administered to one or more spray dryers.


All spray dryers use some type of atomizer or spray nozzle to disperse the liquid or slurry into a controlled drop size spray. The most common of these are rotary nozzles and single fluid pressure swirl nozzles. Alternatively, for some applications two-fluid or ultrasonic nozzles are used. Depending on the process requirements, drop sizes from 10 to 500 micrometers can be achieved with the appropriate nozzle selection. The most common drop sizes are in the 100 to 200 micrometer diameter range. The resulting dry powder is often free-flowing.


The hot drying gas can be passed as a co-current or counter-current flow to the atomizer direction. A co-current flow enables the particles to have a lower residence time within the system and the particle separator (typically a cyclone device) operates more efficiently. The counter-current flow method enables a greater residence time of the particles in the chamber and usually is paired with a fluidized bed system.


Microparticles and/or Encapsulated Active Agent(s)


The subject matter also provides additional embodiments in which microparticles of one or more active agents are produced which are then incorporated into an adhesive formulation or adhesive intermediate. The term “microparticles” as used herein refers to particles having an average diameter or span of from about 0.1 microns to about 500 microns, more preferably from about 1 micron to about 200 microns, more preferably from about 5 microns to about 100 microns, and most preferably from about 5 microns to about 50 microns. The preferred embodiment microparticles can be in a variety of different shapes. For example, the microparticles may be spherical, oblong, or in the form of a thin sheet or flake. The term “span” as used herein refers to the maximum dimension of the particle. Preferably, the microparticles are spherical or generally so.


The microparticles can be relatively homogenous and exhibit a uniform structure throughout their interior or substantially so. Alternatively, the microparticles can include one or more layers and/or discrete interior regions differing in structure, composition, and/or physical characteristics. A preferred configuration for microparticles containing an active agent is that such microparticles contain an outer layer of a polymer or other material that dissolves or otherwise degrades upon exposure to saline, other bodily fluids, or conditions of basic pH, such as a pH greater than 7. The preferred material for the outer layer is generally referred to herein as a water sensitive material and is described in greater detail herein. These preferred microparticles may in other embodiments, include a core which is preferably hydrophilic. Upon incorporation of the preferred microparticles containing an active agent in an adhesive or adhesive intermediate and subsequent use of the adhesive in a medical product, a delayed release of one or more active agents occurs upon exposure to saline or body fluids. That is, once the outer layer of dissolvable or degradable material is removed, an interior layer or region of the microparticles containing the active agent(s) is exposed, thereby enabling migration of the one or more active agents from the microparticles. This strategy provides a convenient technique for establishing long lasting delivery of active agents.


Although not wishing to bound to any particular theory, it is believed that the inclusion of a hydrophilic core in the preferred embodiment microparticles tends to promote incorporation of one or more active agents, and particularly those which are highly hydrophilic. The core of such microparticles can comprise one or multiple active agents. The outer layer or shell in microparticles having a core and shell construction can be hydrophilic or hydrophobic.


As noted, in certain embodiments in which the active agent(s) are formed into microparticles, it may be preferred to provide one or more outer layers of a water sensitive polymer that dissolves or is otherwise removed upon exposure to certain agents. Non-limiting examples of such polymers include starch; materials based on amylase; polysaccharides such as cellulose and derivates, chitin, chitosan, dextran, alginate; proteins such as casein, albumin, gelatin; and synthetic polymers such as polyvinyl pyrolidone, polyethylene oxide, polyvinyl alcohol. Combinations of these materials can be used. For certain charged antimicrobials, a charged polymer can be used to assist in the delivery and/or retention of the antimicrobial.


For embodiments in which one or more active agents are incorporated within the interior of microparticles, the release of the active agent can generally be controlled by the following parameters—the diameter or span of the microparticles, the proportion of water sensitive polymer as compared to the amount of the active agent, the nature of the water sensitive polymer and particularly its dissolution rate, and the chemistry of the adhesive and its sensitivity to moisture, water, or other agents.


The various versions of the preferred embodiment microparticles comprising one or more active agents can be prepared in a variety of techniques. A preferred technique is to use a spray drying operation as described herein to form the noted microparticles. One or more outer layers and preferably layer(s) of a water sensitive material can be applied or otherwise deposited upon the outer surface of the microparticles by techniques known in the art.


In a preferred aspect, microparticles of one or more active agents consisting of a core embedded into a water sensitive polymer are produced by a spray drying process. Upon incorporation in an adhesive matrix, solid microparticles will release the one or more active agents over a relatively long period of time.


Incorporation of Microparticles in Adhesive


As previously noted, for embodiments in which the active agent(s) is in the form of coated microparticles exhibiting a delayed release characteristic, the microparticles can be incorporated directly into an adhesive formulation by blending and/or mixing.


The adhesive containing the microparticles of active agent(s) are then incorporated in a product or used as desired. For example, conventional coating and drying operations can be performed to form an adhesive layer on a medical product. Representative non-limiting examples of such medical products include surgical goods such as incise films, and device fixation products; wound care products; and ostomy pouches.


In certain embodiments, the adhesive can be covered with a carrier, preferably a polyurethane film or any alternative material.


Adhesives


The methods of the present subject matter can be used to incorporate one or more active agents into a wide array of adhesives, and preferably a solvent based adhesive or a hot melt adhesive. Non limiting examples of suitable types of adhesives include acrylic adhesives, rubber adhesives, silicone adhesives, polyurethane adhesives, and variants and combinations thereof. Generally, the resulting microparticles of active agent(s) can be incorporated into nearly any non-aqueous based adhesive. Preferably, the adhesive is a solvent based adhesive. More preferably, the adhesive is a solvent based acrylic adhesive.


The present subject matter also includes combining microparticles of one or more active agent(s) with an adhesive component such as an adhesive ingredient and/or an adhesive premix. This strategy provides an alternative approach for subsequent formation of an adhesive comprising actives in the form of delayed release microparticles.


For embodiments in which the one or more active agents are hydrophilic and in a microparticle form, another advantage results when the microparticles are incorporated into a hydrophobic adhesive matrix. Due to their hydrophilic properties, such active agents will easily release from a hydrophobic adhesive matrix.


The preferred embodiment adhesive compositions include the microparticles as described herein in a proportion of from about 0.01% to about 50% or more, by weight, based upon the total weight of the adhesive. Preferably, the microparticles constitute from about 0.1% to about 40% by weight, and most preferably from about 1% to about 30% by weight of the adhesive composition.


Additional Additives


One or more additional additives can be incorporated into the adhesive and active microparticle formulation. Preferably the additional additives include medicinal compounds. Such medicinal compounds include, but are not limited to, antimicrobials, antibiotics, antifungal agents, antiviral agents, antithrombogenic agents, anesthetics, anti-inflammatory agents, analgesics, anticancer agents, vasodilation substances, wound healing agents, angiogenic agents, angiostatic agents, immune boosting agents, growth factors, and other biological agents. Suitable antimicrobial agents include, but are not limited to, biguanide compounds; triclosan; penicillins; tetracyclines; aminoglycosides, such as gentamicin and Tobramycin™; polymyxins; rifampicins; bacitracins; erythromycins; vancomycins; neomycins; chloramphenicols; miconazole; quinolones, such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enoxacin, and ciprofloxacin; sulfonamides; nonoxynol 9; fusidic acid; cephalosporins; and combinations of such compounds and similar compounds. The additional antimicrobial compounds provide for enhanced antimicrobial activity.


The present subject matter is believed to provide a significant advance in the art. For example, use of the preferred embodiment adhesive composition with delayed release microparticles can provide extended release of one or more active agents over relatively long periods of time, such as over a time period of at least 3 days, or at least 5 days, or at least 7 days for example. Furthermore, the preferred embodiment adhesive formulations can be used to administer two or more otherwise incompatible actives in the same formulation. Thus, one population of microparticles containing a first active and another population of microparticles containing a second active which is incompatible with the first active can be provided. In addition, use of the preferred embodiment adhesives as described herein can be formulated to protect an active agent from oxidation and/or degradation during an adhesive coating process. Moreover, the composition can be tailored to trigger release of the one or more active agents upon occurrence of certain conditions such as for example existence of a particular pH, moisture level, and/or presence of certain enzymes.


Many other benefits will no doubt become apparent from future application and development of this technology.


All patents, published applications, and articles noted herein are hereby incorporated by reference in their entirety.


It will be understood that any one or more feature or component of one embodiment described herein can be combined with one or more other features or components of another embodiment. Thus, the present subject matter includes any and all combinations of components or features of the embodiments described herein.


As described hereinabove, the present subject matter solves many problems associated with previous type products, adhesives and practices. However, it will be appreciated that various changes in the details, materials and arrangements of components and operations, which have been herein described and illustrated in order to explain the nature of the subject matter, may be made by those skilled in the art without departing from the principle and scope of the subject matter, as expressed in the appended claims.

Claims
  • 1. An adhesive composition comprising: an adhesive;microparticles dispersed in the adhesive, the microparticles including a matrix material and at least one active agent;wherein at least one active agent is hydrophilic;wherein at least one active agent is chlorhexadine gluconate;wherein the matrix material is a saccharide binder;wherein the adhesive is selected from the group consisting of acrylic adhesives, rubber adhesives, and combinations thereof; andwherein the microparticles further include an outer layer of a water sensitive material that dissolves or otherwise degrades upon exposure to at least one of (i) saline, (ii) other bodily fluids, and basic pH.
  • 2. The adhesive of claim 1 wherein the water sensitive material includes an agent selected from the group consisting of starch, materials based on amylase, polysaccharides, proteins, synthetic polymers, and combinations thereof.
  • 3. The adhesive of claim 2 wherein the water sensitive material is starch.
  • 4. The adhesive of claim 2 wherein the water sensitive material is a material based on amylase.
  • 5. The adhesive of claim 2 wherein the water sensitive material is a polysaccharide.
  • 6. The adhesive of claim 5 wherein the polysaccharide is selected from the group consisting of cellulose and its derivatives, chitin, chitosan, dextran, alginate, and combinations thereof.
  • 7. The adhesive of claim 2 wherein the water sensitive material is a protein.
  • 8. The adhesive of claim 7 wherein the protein is selected form the group consisting of casein, albumin, gelatine, and combinations thereof.
  • 9. The adhesive of claim 2 wherein the water sensitive material is a synthetic polymer.
  • 10. The adhesive of claim 9 wherein the synthetic polymer is selected from the group consisting of polyvinyl pyrolidone, polyethylene oxide, polyvinyl alcohol, and combinations thereof.
  • 11. The adhesive composition of claim 1 wherein the microparticles constitute from about 0.01% to about 50% by weight of the total weight of the composition.
  • 12. The adhesive composition of claim 11 wherein the microparticles constitute from about 0.1% to about 40% by weight of the total weight of the composition.
  • 13. The adhesive composition of claim 12 wherein the microparticles constitute from about 1% to about 30% by weight of the total weight of the composition.
CROSS REFERENCES TO RELATED APPLICATIONS

The present application is a 371 of International Application No. PCT/US2012/037429, which was published in English on Nov. 22, 2012, which claims priority to U.S. Provisional Patent Application No. 61/486,379 filed May 16, 2011, which is incorporated herein by reference in its entirety.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2012/037429 5/11/2012 WO 00 11/13/2013
Publishing Document Publishing Date Country Kind
WO2012/158483 11/22/2012 WO A
US Referenced Citations (93)
Number Name Date Kind
2736721 Dexter Feb 1956 A
4199567 Rankin Apr 1980 A
4310509 Berglund et al. Jan 1982 A
4434181 Marks, Sr. et al. Feb 1984 A
4460369 Seymour Jul 1984 A
4600001 Gilman Jul 1986 A
4753232 Ward Jun 1988 A
4941882 Ward et al. Jul 1990 A
4990144 Blott Feb 1991 A
5018516 Gilman May 1991 A
5069907 Mixon et al. Dec 1991 A
5214119 Leir et al. May 1993 A
5270358 Asmus Dec 1993 A
5322695 Shah et al. Jun 1994 A
5340581 Tseng et al. Aug 1994 A
5382451 Johnson et al. Jan 1995 A
5389376 Duan et al. Feb 1995 A
5441741 Cheong Aug 1995 A
5614310 Delgado et al. Mar 1997 A
5686096 Khan et al. Nov 1997 A
5702721 Horstmann et al. Dec 1997 A
5717005 Richardson Feb 1998 A
5763412 Khan et al. Jun 1998 A
5908693 Delgado Jun 1999 A
6043406 Sessions et al. Mar 2000 A
6228354 Jeng May 2001 B1
6455086 Trinh et al. Sep 2002 B1
6458341 Rozzi et al. Oct 2002 B1
6495158 Buseman et al. Dec 2002 B1
6518359 Clemens et al. Feb 2003 B1
6565873 Shefer et al. May 2003 B1
6589562 Shefer et al. Jul 2003 B1
6599525 Scamilla Aledo et al. Jul 2003 B2
6642304 Hansen et al. Nov 2003 B1
6733745 Rozzi et al. May 2004 B2
6742522 Baker Jun 2004 B1
6844306 Werle et al. Jan 2005 B2
6893655 Flanigan et al. May 2005 B2
7160976 Luhmann et al. Jan 2007 B2
7674473 Falder et al. Mar 2010 B2
7683216 Dubois et al. Mar 2010 B2
7704523 Serafica et al. Apr 2010 B2
7824122 Flores et al. Nov 2010 B2
8623935 Hobbs et al. Jan 2014 B2
8969649 Leibowitz et al. Mar 2015 B2
9101134 Huang et al. Aug 2015 B2
9278155 Asmus et al. Mar 2016 B2
9346981 Wibaux et al. May 2016 B2
9592161 Rule et al. Mar 2017 B2
9764059 Wibaux et al. Sep 2017 B2
9801902 Smith et al. Oct 2017 B2
10329384 Hansen et al. Jun 2019 B2
10456498 Wibaux Oct 2019 B2
20020018814 Werle et al. Feb 2002 A1
20020072480 Werle et al. Jun 2002 A1
20030077316 Nichols et al. Apr 2003 A1
20030212005 Petito Nov 2003 A1
20040009202 Woller Jan 2004 A1
20040063792 Khera et al. Apr 2004 A1
20040109869 Glenn et al. Jun 2004 A1
20040170794 Verhaert Sep 2004 A1
20040241214 Kirkwood Dec 2004 A1
20050049365 Cleary et al. Mar 2005 A1
20050118246 Wong et al. Jun 2005 A1
20050244346 Nakao et al. Nov 2005 A1
20050249791 Hobbs et al. Nov 2005 A1
20070116729 Paiepu May 2007 A1
20070259029 McEntire et al. Nov 2007 A1
20080220045 Shalaby et al. Sep 2008 A1
20080233177 Meconi Sep 2008 A1
20090130157 Ylitalo et al. May 2009 A1
20100022654 Asmus et al. Jan 2010 A1
20100029779 Street et al. Feb 2010 A1
20100081672 Wan et al. Apr 2010 A1
20100303878 Slager et al. Dec 2010 A1
20100322996 Wibaux et al. Dec 2010 A1
20110067799 Mussig et al. Mar 2011 A1
20120078155 Bowman et al. Mar 2012 A1
20120245538 Horstmann et al. Sep 2012 A1
20120328682 Bardwell et al. Dec 2012 A1
20130072566 Asmus et al. Mar 2013 A1
20130239977 McGuire, Jr. Sep 2013 A1
20130243841 Kommareddy et al. Sep 2013 A1
20130303656 Wibaux et al. Nov 2013 A1
20140322299 Wibaux Oct 2014 A1
20150056291 Wibaux et al. Feb 2015 A1
20150367021 Wibaux Dec 2015 A1
20160000609 Van Holten et al. Jan 2016 A1
20160030248 Potters Feb 2016 A1
20160228600 Wibaux et al. Aug 2016 A1
20170007464 Liu et al. Jan 2017 A1
20170095431 Andrews et al. Apr 2017 A1
20200016291 Wibaux Jan 2020 A1
Foreign Referenced Citations (56)
Number Date Country
1985043241 Dec 1985 AU
1207228 Jul 1986 CA
2333009 Dec 1999 CA
1522687 Aug 2004 CN
1961666 May 2007 CN
101653431 Feb 2010 CN
0066899 Dec 1982 EP
0404558 Dec 1990 EP
0328421 Apr 1993 EP
0361722 Dec 1993 EP
1139981 Apr 2002 EP
1203531 Nov 2003 EP
1784232 May 2007 EP
3280769 Feb 2018 EP
3368086 Sep 2018 EP
2968014 Apr 2019 EP
2274586 Aug 1994 GB
1990-147063 Jun 1990 JP
1994508287 Sep 1994 JP
6-509955 Nov 1994 JP
2825549 Nov 1998 JP
2002179513 Jun 2002 JP
2002-272831 Sep 2002 JP
2002-332228 Nov 2002 JP
2003534310 Nov 2003 JP
2004010545 Jan 2004 JP
2007502319 Feb 2007 JP
2007-526348 Sep 2007 JP
2007-536261 Dec 2007 JP
2014510038 Apr 2014 JP
9013780 Nov 1990 WO
199300118 Jan 1993 WO
WO9300118 Jan 1993 WO
1993002717 Feb 1993 WO
WO199302717 Feb 1993 WO
199303649 Mar 1993 WO
WO9303649 Mar 1993 WO
WO1999000025 Jan 1999 WO
1999023150 May 1999 WO
WO992470 Dec 1999 WO
WO2000036353 Jun 2000 WO
2000061692 Oct 2000 WO
WO2000061692 Oct 2000 WO
2003103618 Dec 2003 WO
2004080499 Sep 2004 WO
2009064291 May 2009 WO
WO2010080936 Jul 2010 WO
2011009083 Jan 2011 WO
WO2011088072 Jul 2011 WO
WO2012100244 Jul 2012 WO
WO2013074628 May 2013 WO
2013090191 Jun 2013 WO
2014124232 Aug 2014 WO
2014151355 Sep 2014 WO
2015188031 Dec 2015 WO
2015187632 Dec 2015 WO
Non-Patent Literature Citations (29)
Entry
Internationai Search Report and Written Opinion issued in correspanding IA No. PCT/US2012/037429 dated Jan. 21, 2013.
Giunchedi, et al. “Formulation and in vivo evaluation of chlorhexidine buccal tablets prepared using drug-loaded chitosan microspheres,” European Journal of Pharmaceutics and Biopharmaceutics, Elsevier Science Publishers B.V., Amsterdam, NL, vol. 53, No. 2, Mar. 1, 2002, pp. 233-239, XP004342819, ISSN: 0939-6411, DOI: 10.1016/S0939-6411(01)00237-5 Section 2.2 Preparation by spray-drying; table 2.
International Search Report and Written Opinion issued in corresponding IA No. PCT/US2012/022162 dated Aug. 10, 2012.
Avery Dennison Medical Solutions Demonstrates the Efficacy of its new Chlorhexidine Gluconate Adhesive Delivery System, Avery Dennison Medical Solutions, Sep. 13, 2011, 1-2.
Boddupalli, et al., Mucoadhesive drug delivery system: An overview, Jounal of Advanced Pharmaceutical Technology & Research, vol. 1, 2010, 381-387.
Ceballos, et al., Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets, II Farmaco, Jan. 15, 2005, 913-918, vol. 60, No. 11-12.
Cui, et al., Bilayer Films for Mucosal (Genetic) Immunization via the Buccal Route in Rabbits, Pharmaceutical Research, Jul. 2002, 947-953, vol. 19, No. 7.
Eudragit, acrylic polymers for solid oral dosage forms, Jan. 1, 2008, 1-11.
International Search Report and Written Opinion issued in corresponding IA No. PCT/US2014/025549 dated Jul. 25, 2014.
International Search Report and Written Opinion of the International Searching Authority, or the Declaration issued in corresponding IA No. PCMS14/15263 dated Sep. 19, 2014.
International Search Report and Written Opinion of the International Searching Authority, or the Declaration issued in corresponding IA No. PCT/US2015/033689 dated Sep. 8, 2015.
International Search Report and Written Opinion of the International Searching Authority, or the Declaration issued in corresponding IA No. PCT/US2012/065014 dated Feb. 15, 2013.
Invitation to Pay Additional Fees issued in corresponding IA No. PCT/US2012/022162.
Maruzen, “New Experimental Chemistry Course 1 Basic Operation I”, Sep. 20, 1975, 459-463.
Yue, et al., A novel polymeric chlorhexidine delivery device for the treatment of periodontal disease, Biomaterials, vol. 25, 2004, pp. 3743-3750.
International Search Report and Written Opinion of the International Searching Authority, or the Declaration issued in corresponding IA No. PCT/US2015/034336 dated Mar. 23, 2016.
International Preliminary Report on Patentability dated Nov. 19, 2013 issued in corresponding IA No. PCT/US2012/037429 filed May 11, 2012.
Pei, et al. “Plant Fiber Chemistry”, pp. 244-246, China Light Industry Press, Jul. 2012.
International Preliminary Report on Patentability dated May 20, 2014 issued in corresponding IA No. PCT/US2012/065014 filed Nov. 14, 2012.
Sateesh Kandavilli: “Polymers in Transdermal Drug Delivery Systems,” Pharmaceutical Technology, May 31, 2002, XP055101101, Retrieved from the internet:. http://www.pharamtech.com/pharmtech/data/articlestandard/pharmtech/192002/18600/article.pdf [retrieved on Feb. 10, 2014].
Luo, et al., A Complete Collection of Pharmaceutical Excipients, Sichuan university of science and technology press, Jan. 31, 2006, 53-56.
International Preliminary Report on Patentability dated Dec. 6, 2016 issued in corresponding IA No. PCT/US2015/034336 filed Jun. 5, 2015.
He et al., General Practitioner' s Guidelines for Medication Use, Beijing Science and Technology Press, Nov. 30, 2010, 1205.
Yao, Application Directory of Pharmaceutical Excipients, China Medical Science and Technology Press, Aug. 31, 2011, 1342-1347.
International Preliminary Report on Patentability dated Jul. 6, 2015 issued in corresponding IA No. PCT/US2014/015263 filed Feb. 7, 2014.
Invitation to Pay Additional Fees dated May 22, 2014 issued in corresponding IA No. PCT/US2014/015263 filed Feb. 7, 2014.
International Preliminary Report on Patentability dated Sep. 24, 2015 issued in corresponding IA No. PCT/US2014/025549 filed Mar. 13, 2014.
International Preliminary Report on Patentability dated Jul. 23, 2013 issued in corresponding IA No. PCT/US2012/022162 filed Jan. 23, 2012.
International Preliminary Report Patentability dated Dec. 6, 2016 issued in corresponding IA No. PCT/US2015/033689 filed Jun. 2, 2015.
Related Publications (1)
Number Date Country
20150056291 A1 Feb 2015 US
Provisional Applications (1)
Number Date Country
61486379 May 2011 US